News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
290,864 Results
Type
Article (15228)
Company Profile (326)
Press Release (275304)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (80898)
Career Advice (182)
Deals (14956)
Drug Delivery (42)
Drug Development (50864)
Employer Resources (33)
FDA (5888)
Job Trends (5344)
News (148197)
Policy (10408)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (960)
Accelerated approval (19)
Adcomms (14)
Allergies (82)
Alliances (22044)
ALS (125)
Alzheimer's disease (1056)
Antibody-drug conjugate (ADC) (241)
Approvals (6078)
Artificial intelligence (258)
Autoimmune disease (110)
Automation (9)
Bankruptcy (107)
Best Places to Work (4700)
BIOSECURE Act (6)
Biosimilars (100)
Biotechnology (241)
Bladder cancer (101)
Brain cancer (45)
Breast cancer (346)
Cancer (3148)
Cardiovascular disease (241)
Career advice (166)
Career pathing (8)
CAR-T (218)
CDC (5)
Cell therapy (565)
Cervical cancer (15)
Clinical research (43793)
Collaboration (1162)
Company closure (2)
Compensation (591)
Complete response letters (40)
COVID-19 (1106)
CRISPR (86)
C-suite (552)
Cystic fibrosis (112)
Data (4340)
Denatured (15)
Depression (92)
Diabetes (255)
Diagnostics (1533)
Digital health (11)
Diversity (5)
Diversity, equity & inclusion (10)
Drug discovery (188)
Drug pricing (52)
Drug shortages (5)
Duchenne muscular dystrophy (213)
Earnings (31953)
Editorial (25)
Employer branding (4)
Employer resources (31)
Events (52585)
Executive appointments (625)
FDA (7645)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (22)
Funding (991)
Gene editing (183)
Generative AI (21)
Gene therapy (488)
GLP-1 (513)
Government (1210)
Grass and pollen (3)
Guidances (170)
Healthcare (6915)
HIV (19)
Huntington's disease (43)
IgA nephropathy (74)
Immunology and inflammation (190)
Immuno-oncology (39)
Indications (66)
Infectious disease (1211)
Inflammatory bowel disease (156)
Inflation Reduction Act (10)
Influenza (39)
Intellectual property (168)
Interviews (19)
IPO (8810)
IRA (13)
Job creations (909)
Job search strategy (147)
JPM (40)
Kidney cancer (9)
Labor market (22)
Layoffs (244)
Leadership (9)
Legal (1567)
Liver cancer (42)
Longevity (11)
Lung cancer (420)
Lymphoma (248)
Machine learning (24)
Management (7)
Manufacturing (379)
MASH (131)
Medical device (2836)
Medtech (2845)
Mergers & acquisitions (6845)
Metabolic disorders (732)
Multiple sclerosis (110)
NASH (13)
Neurodegenerative disease (232)
Neuropsychiatric disorders (70)
Neuroscience (1988)
Neurotech (1)
NextGen: Class of 2026 (2124)
Non-profit (945)
Now hiring (30)
Obesity (333)
Opinion (129)
Ovarian cancer (131)
Pain (102)
Pancreatic cancer (161)
Parkinson's disease (234)
Partnered (13)
Patents (304)
Patient recruitment (330)
Peanut (44)
People (26887)
Pharmaceutical (50)
Pharmacy benefit managers (6)
Phase 1 (15508)
Phase 2 (20354)
Phase 3 (12855)
Pipeline (3262)
Policy (95)
Postmarket research (858)
Preclinical (6559)
Press Release (30)
Prostate cancer (146)
Psychedelics (50)
Radiopharmaceuticals (239)
Rare diseases (648)
Real estate (1598)
Recruiting (14)
Regulatory (10018)
Reports (19)
Research institute (1021)
Resumes & cover letters (18)
Rett syndrome (24)
RNA editing (21)
RSV (16)
Schizophrenia (123)
Series A (186)
Series B (140)
Service/supplier (3)
Sickle cell disease (77)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (16)
Startups (2030)
State (1)
Stomach cancer (5)
Supply chain (33)
Tariffs (20)
The Weekly (62)
Vaccines (334)
Venture capital (70)
Weight loss (176)
Women's health (25)
Worklife (2)
Date
Last 7 days (348)
Last 30 days (1227)
Last 365 days (18114)
2026 (1687)
2025 (18405)
2024 (20948)
2023 (22851)
2022 (27640)
2021 (28993)
2020 (24924)
2019 (16954)
2018 (12246)
2017 (14144)
2016 (12143)
2015 (14792)
2014 (10689)
2013 (7746)
2012 (7767)
2011 (7835)
2010 (7617)
Location
Africa (158)
Alabama (66)
Alaska (3)
Arizona (73)
Arkansas (5)
Asia (18589)
Australia (3178)
California (7168)
Canada (1847)
China (778)
Colorado (255)
Connecticut (262)
Delaware (235)
Europe (39767)
Florida (908)
Georgia (210)
Hawaii (2)
Idaho (17)
Illinois (403)
India (35)
Indiana (166)
Iowa (8)
Japan (222)
Kansas (81)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (747)
Massachusetts (5684)
Michigan (112)
Minnesota (258)
Mississippi (3)
Missouri (36)
Montana (16)
Nebraska (5)
Nevada (34)
New Hampshire (21)
New Jersey (1725)
New Mexico (13)
New York (1807)
North Carolina (839)
North Dakota (6)
Northern California (3525)
Ohio (182)
Oklahoma (11)
Oregon (25)
Pennsylvania (1291)
Puerto Rico (9)
Rhode Island (25)
South America (225)
South Carolina (9)
Southern California (2832)
Tennessee (41)
Texas (926)
United States (23795)
Utah (104)
Virginia (137)
Washington D.C. (39)
Washington State (615)
West Virginia (1)
Wisconsin (45)
290,864 Results for "avenue therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics
November 6, 2025
·
7 min read
Press Releases
Feinstein Institutes’ Research Pinpoints Core Cause of Vascular Cognitive Impairment, Unlocking New Therapeutic Avenues for Cognitive Decline
December 8, 2025
·
3 min read
Press Releases
Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital
January 8, 2026
·
5 min read
Press Releases
Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital
December 17, 2025
·
6 min read
Deals
Avenue Therapeutics Announces Reverse Stock Split
Avenue Therapeutics, Inc. today announced that it will effect a 1-for-75 reverse split of its issued and outstanding common stock.
April 24, 2024
·
7 min read
Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer of Avenue Therapeutics, will present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference.
June 20, 2024
·
1 min read
Business
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
Avenue Therapeutics, Inc. today reported financial results and recent corporate highlights for the first quarter ended March 31, 2024.
May 15, 2024
·
11 min read
Deals
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
Avenue Therapeutics, Inc. today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase an aggregate of 689,680 shares of the Company’s common stock.
April 29, 2024
·
7 min read
Business
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported financial results and recent corporate highlights for the year ended December 31, 2023.
March 18, 2024
·
12 min read
Deals
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq
Avenue Therapeutics, Inc. today announced that by decision dated March 11, 2024, the Nasdaq Hearings Panel granted the Company’s request for an extension to evidence compliance with all applicable criteria for continued listing on The Nasdaq Capital Market.
March 15, 2024
·
4 min read
1 of 29,087
Next
